Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
LEVETIRACETAM IN SODIUM CHLORIDE vs AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Levetiracetam binds to synaptic vesicle glycoprotein 2A (SV2A), modulating neurotransmitter release and reducing neuronal hyperexcitability.
Aminoglycoside antibiotic that irreversibly binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibiting bacterial protein synthesis.
Adjunctive therapy in the treatment of partial-onset seizures in adults and children ≥1 month,Adjunctive therapy in myoclonic seizures in adults and children ≥12 years with juvenile myoclonic epilepsy,Adjunctive therapy in primary generalized tonic-clonic seizures in adults and children ≥6 years with idiopathic generalized epilepsy
Treatment of serious gram-negative bacterial infections (e.g., Pseudomonas aeruginosa, Escherichia coli, Klebsiella species),Used in combination for severe infections such as sepsis, pneumonia, complicated urinary tract infections, and intra-abdominal infections
500-1500 mg IV every 12 hours; initial dose 1000 mg/day, titrate by 1000 mg/day every 2 weeks up to 3000 mg/day.
15 mg/kg/day IV divided every 8-12 hours or 15-20 mg/kg IV once daily; typical adult dose: 500-1000 mg IV every 8-12 hours.
6-8 hours in adults; prolonged in elderly (10-11 h) and renal impairment (up to 25 h in ESRD)
The terminal elimination half-life is approximately 2-3 hours in adults with normal renal function. In neonates, it may be prolonged to 4-8 hours. In patients with impaired renal function, half-life can extend to 30-80 hours or more, necessitating dose adjustment based on creatinine clearance.
Levetiracetam is primarily eliminated renally; approximately 24% undergoes metabolism by hydrolysis of the acetamide group, not dependent on CYP450 enzymes.
Amikacin is minimally metabolized; primarily eliminated unchanged by glomerular filtration.
66% renal (unchanged), 27% as inactive metabolite (UCB L057) via renal; <1% fecal
Amikacin is eliminated primarily by glomerular filtration. Approximately 94-98% of an administered dose is excreted unchanged in the urine within 24 hours in patients with normal renal function. Less than 1% is excreted in bile or feces.
<10% (negligible); not bound to albumin or alpha-1-acid glycoprotein
Amikacin has low protein binding, ranging from 0-11%. It binds primarily to albumin, but due to low binding, protein binding alterations do not significantly impact pharmacokinetics.
0.5-0.7 L/kg; approximates total body water, indicating extensive distribution into tissues and CNS
The volume of distribution is approximately 0.25-0.4 L/kg in adults. It reflects distribution primarily into extracellular fluid. The Vd is increased in conditions such as edema, ascites, and sepsis, and is decreased in dehydration. In neonates, the Vd is larger (0.5-0.6 L/kg) due to higher extracellular fluid volume.
IV: 100%; Oral: 100% (rapid and complete absorption)
Intramuscular: Nearly complete, with bioavailability >90%. Oral: Not bioavailable due to negligible gastrointestinal absorption (<1%). Intravenous: 100%.
Cr Cl >80 m L/min: 500-1500 mg every 12h; Cr Cl 50-80: 500-1000 mg every 12h; Cr Cl 30-50: 250-750 mg every 12h; Cr Cl <30: 250-500 mg every 12h; ESRD: 500-1000 mg every 24h with 250-500 mg supplement post-dialysis.
Cr Cl 30-60 m L/min: administer every 12-24 hours; Cr Cl 15-29 m L/min: administer every 24-48 hours; Cr Cl <15 m L/min: administer every 48-72 hours. Use therapeutic drug monitoring.
No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B). Severe impairment (Child-Pugh C): reduce maintenance dose by 50%.
No dosage adjustment required for hepatic impairment.
1 month to <6 months: 7 mg/kg/dose IV every 12h; 6 months to <4 years: 10 mg/kg/dose IV every 12h; 4 to <16 years: 10 mg/kg/dose IV every 12h up to 30 mg/kg/day. Maximum 3000 mg/day.
Neonates: 15-20 mg/kg IV every 24 hours; Infants and children: 15-20 mg/kg IV every 8-24 hours depending on age and renal function. Not to exceed 1.5 g/day.
Initiate at 500 mg twice daily, titrate slowly due to age-related renal function decline; adjust dose per creatinine clearance.
Reduce initial dose based on renal function; monitor serum creatinine and drug levels; typical starting dose: 7.5 mg/kg IV every 24 hours adjusted for Cr Cl.
No FDA black box warnings.
Aminoglycosides, including amikacin, are associated with nephrotoxicity and ototoxicity (both auditory and vestibular), which can occur even at therapeutic doses. Risk is increased with prolonged use, higher doses, renal impairment, and concurrent use of other nephrotoxic or ototoxic drugs. Monitoring of renal function and serum drug levels is essential.
Behavioral and psychiatric symptoms: aggression, agitation, anger, anxiety, depression, mood swings, psychosis, suicidal ideation,Somnolence and fatigue,Serious dermatological reactions (e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis),Hematologic abnormalities (e.g., decreased white blood cell counts),Hypersensitivity reactions including angioedema,Renal impairment requires dose adjustment
Neurotoxicity (including ototoxicity and nephrotoxicity) may occur. Risk of neuromuscular blockade, especially in patients with neuromuscular disorders or receiving anesthetics. Monitor renal function, audiometric tests, and serum drug concentrations. Use with caution in elderly, dehydrated, or renally impaired patients. Avoid concomitant use of other nephrotoxic or ototoxic agents.
Hypersensitivity to levetiracetam or any component of the formulation
Hypersensitivity to amikacin or any aminoglycoside; history of aminoglycoside-associated ototoxicity or nephrotoxicity; myasthenia gravis (risk of neuromuscular blockade).
No significant food interactions. Levetiracetam can be taken with or without food. Avoid excessive alcohol consumption as it may increase CNS depression.
No significant food interactions. Maintain adequate hydration unless contraindicated. No specific dietary restrictions.
Levetiracetam is associated with an increased risk of major congenital malformations, particularly neural tube defects, when used during the first trimester. Exposure in the second and third trimesters may lead to fetal growth restriction and neurodevelopmental effects. The risk appears dose-dependent.
Amikacin is an aminoglycoside antibiotic. There are no adequate and well-controlled studies in pregnant women. Aminoglycosides can cause fetal harm when administered to a pregnant woman. There is a potential for fetal ototoxicity and nephrotoxicity. First trimester: Risks unknown but avoid if possible. Second/Third trimester: Use only if clearly needed and if benefit outweighs risk; associated with irreversible bilateral congenital deafness when administered during pregnancy.
Levetiracetam is excreted into human breast milk with a milk-to-plasma (M/P) ratio of approximately 1.0. Infant exposure is estimated to be 1-2% of the maternal weight-adjusted dose. No adverse effects have been reported in breastfed infants, but caution is recommended.
Amikacin is excreted in human milk in low concentrations. The M/P ratio is approximately 0.15-0.5. Based on limited data, the dose to the infant is estimated to be <1% of maternal dose. Use with caution in nursing mothers; monitor infant for diarrhea, candidiasis, and potential allergic reactions. Consider the benefits of breast-feeding and the importance of amikacin to the mother.
Pregnancy may decrease levetiracetam plasma concentrations by up to 40-60% due to increased clearance. Dose adjustment is often required: monitor serum trough levels and increase dose as needed to maintain therapeutic levels. Postpartum, monitor for potential dose reduction.
Pregnancy may alter pharmacokinetics due to increased volume of distribution and renal blood flow. However, specific dosing adjustments for amikacin in pregnancy are not well established. Monitor serum drug concentrations (peak and trough) to guide dosing, especially in patients with renal impairment or prolonged therapy. Use standard dosing with careful monitoring.
Monitor for behavioral and psychiatric symptoms, especially in pediatric patients. Infusion rate should not exceed 5 mg/kg/min. Risk of suicidal thoughts and behavior. Caution in renal impairment; adjust dose based on creatinine clearance. Levetiracetam is not significantly protein-bound and has minimal drug interactions. May cause somnolence, dizziness, and coordination difficulties.
Avoid concomitant use with other nephrotoxic or ototoxic drugs (e.g., loop diuretics, vancomycin). Monitor peak (25-35 mcg/m L) and trough (<8 mcg/m L) serum levels to guide dosing and reduce toxicity risk. Extended-interval (once-daily) dosing is preferred in many patients; adjust for renal function using ideal body weight. In obese patients, dose based on adjusted body weight. Rapid infusion can cause neuromuscular blockade; use with caution in myasthenia gravis or concurrent neuromuscular blocking agents.
Report any new or worsening depression, agitation, hostility, or suicidal thoughts immediately.,Do not drive or operate heavy machinery until you know how levetiracetam affects you; it may cause dizziness or sleepiness.,If you miss a dose, take it as soon as you remember unless it is almost time for your next dose; do not double dose.,Do not stop taking levetiracetam abruptly; this can increase seizure frequency.,Inform all healthcare providers that you take levetiracetam, especially before surgery or emergency treatment.
This medication is given intravenously and will be monitored closely by your healthcare team.,Report any new hearing loss, ringing in the ears, dizziness, or difficulty urinating immediately.,Do not skip or double doses; adhere to the prescribed schedule.,Inform your doctor if you are pregnant, breastfeeding, or have kidney disease.
"Levetiracetam, an antiepileptic drug, may potentiate the sedative effects of pramipexole, a dopamine agonist used for Parkinson's disease and restless legs syndrome. This additive pharmacodynamic interaction results in increased central nervous system depression, leading to enhanced drowsiness, dizziness, and impaired psychomotor function. Clinically, patients may experience excessive sedation, reduced alertness, and an increased risk of falls or accidents, particularly during treatment initiation or dose adjustments."
"Butorphanol, a mixed agonist-antagonist opioid, and levetiracetam, an antiepileptic, both lower the seizure threshold and can cause central nervous system (CNS) depression. Coadministration may result in additive CNS depression, leading to excessive sedation, respiratory depression, and an increased risk of seizures, especially in patients with epilepsy or head trauma. Clinically, this combination can provoke breakthrough seizures and worsen cognitive and psychomotor impairment."
"Thiothixene, a typical antipsychotic, can lower the seizure threshold, increasing the risk of convulsions, particularly in patients with epilepsy. Levetiracetam, an anticonvulsant, may be less effective if seizure threshold is reduced, potentially leading to breakthrough seizures. Additionally, both drugs can cause CNS depression, leading to additive sedation, dizziness, and impaired cognitive function."
"Amikacin, an aminoglycoside antibiotic, may competitively inhibit the renal tubular secretion and potentially reduce the clearance of masoprocol, a dicarboxylic acid derivative used as a chemotherapeutic agent. This interaction could lead to increased systemic exposure to masoprocol, elevating the risk of dose-dependent toxicities such as severe enteritis, myelosuppression, and hepatotoxicity. Given the narrow therapeutic index of masoprocol, even modest elevations in serum levels may result in clinically significant adverse outcomes."
"Amikacin, an aminoglycoside antibiotic, may competitively inhibit the tubular secretion of mycophenolic acid (MPA) in the renal proximal tubules, leading to reduced renal clearance of MPA. This interaction can result in elevated serum levels of MPA, increasing the risk of dose-related toxicities such as bone marrow suppression (leukopenia, thrombocytopenia), gastrointestinal disturbances, and increased susceptibility to infections. Patients receiving this combination should be closely monitored for signs of MPA toxicity, especially those with pre-existing renal impairment."
"Coadministration of Metocurine, a nondepolarizing neuromuscular blocking agent, with Amikacin, an aminoglycoside antibiotic, may result in enhanced and prolonged neuromuscular blockade. Aminoglycosides can impair acetylcholine release from presynaptic nerve terminals and reduce postsynaptic sensitivity, synergistically augmenting the effects of nondepolarizing agents. This interaction can lead to excessive muscle relaxation, including respiratory muscle paralysis, increasing the risk of apnea and postoperative respiratory depression."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about LEVETIRACETAM IN SODIUM CHLORIDE vs AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, answered by our medical review team.
LEVETIRACETAM IN SODIUM CHLORIDE is a Electrolyte that works by Levetiracetam binds to synaptic vesicle glycoprotein 2A (SV2A), modulating neurotransmitter release and reducing neuronal hyperexcitability.. AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is a Electrolyte that works by Aminoglycoside antibiotic that irreversibly binds to the 30S ribosomal subunit, causing misreading of m RNA and inhibiting bacterial protein synthesis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between LEVETIRACETAM IN SODIUM CHLORIDE and AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of LEVETIRACETAM IN SODIUM CHLORIDE is: 500-1500 mg IV every 12 hours; initial dose 1000 mg/day, titrate by 1000 mg/day every 2 weeks up to 3000 mg/day.. The standard adult dose of AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is: 15 mg/kg/day IV divided every 8-12 hours or 15-20 mg/kg IV once daily; typical adult dose: 500-1000 mg IV every 8-12 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between LEVETIRACETAM IN SODIUM CHLORIDE and AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. LEVETIRACETAM IN SODIUM CHLORIDE is classified as Category A/B. Levetiracetam is associated with an increased risk of major congenital malformations, particularly neural tube defects, when used during the first trimester. Exposure in the second. AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is classified as Category A/B. Amikacin is an aminoglycoside antibiotic. There are no adequate and well-controlled studies in pregnant women. Aminoglycosides can cause fetal harm when administered to a pregnant . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.